Patents by Inventor Jörg SCHEUERMANN
Jörg SCHEUERMANN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230381324Abstract: A binding moiety (B) for Carbonic Anhydrase IX (CAIX), the binding moiety comprising: The binding moiety is univalent, bivalent, or multivalent. A targeted therapeutic agent may comprise the binding moiety. The invention also includes a method for treating a disease expressing elevated levels of CAIX by administering the targeted therapeutic agent.Type: ApplicationFiled: February 17, 2023Publication date: November 30, 2023Applicant: Eidgenoessiche Technische Hochschule ZurichInventors: Nikolaus Krall, Willy Decurtins, Dario Neri, Jörg Scheuermann, Moreno Wichert
-
Publication number: 20230357757Abstract: This invention relates to methods for producing nucleic acid encoded compounds and libraries of nucleic acid encoded compounds. A nascent compound that comprises a scaffold connected to a solid support by a linker is covalently attached to one or more chemical building blocks to form a chemical portion attached to the scaffold. Coding oligonucleotides encoding the one or more chemical building blocks are covalently attached to the nascent compound to form a coding nucleic acid portion attached to the scaffold. A cleaving group is attached to the chemical portion, nucleic acid portion, or scaffold of the compound. The linker is then reacted with the cleaving group, such that the linker is cleaved and the compound released from the solid support. Nucleic acid encoded compounds and libraries and methods for their production are provided.Type: ApplicationFiled: October 21, 2021Publication date: November 9, 2023Inventors: Dario Neri, Jörg Scheuermann, Michelle Keller, Dimitar Petrov, Yuichi Onda, Gabriele Bassi
-
Publication number: 20210308269Abstract: A binding moiety (B) for Carbonic Anhydrase IX (CAIX), the binding moiety comprising: The binding moiety is univalent, bivalent, or multivalent. A targeted therapeutic agent may comprise the binding moiety. The invention also includes a method for treating a disease expressing elevated levels of CAIX by administering the targeted therapeutic agent.Type: ApplicationFiled: March 23, 2021Publication date: October 7, 2021Applicant: Eidgenoessische Technische Hochschule ZurichInventors: Nikolaus Krall, Willy Decurtins, Dario Neri, Jörg Scheuermann, Moreno Wichert
-
Publication number: 20200123534Abstract: This invention relates to the synthesis of nucleic acid-encoded chemical libraries using common adaptor sequences. Nucleic acid strands coupled to chemical moieties may be contacted with identifier oligonucleotides comprising coding sequences encoding the chemical moieties and an adaptor oligonucleotides, such that the adaptor oligonucleotide hybridizes to both the nucleic acid strands and the identifier oligonucleotides to allow ligation of the identifier oligonucleotides to the nucleic acid strands. The adaptor oligonucleotide is then removed. Nucleic acid-encoded chemical libraries, and methods of producing or screening such libraries are provided.Type: ApplicationFiled: March 26, 2019Publication date: April 23, 2020Inventors: Willy Decurtins, Raphael Franzini, Dario Neri, Jorg Scheuermann, Moreno Wichert
-
Patent number: 10240147Abstract: This invention relates to the synthesis of nucleic acid-encoded chemical libraries using common adaptor sequences. Nucleic acid strands coupled to chemical moieties may be contacted with identifier oligonucleotides comprising coding sequences encoding the chemical moieties and an adaptor oligonucleotides, such that the adaptor oligonucleotide hybridizes to both the nucleic acid strands and the identifier oligonucleotides to allow ligation of the identifier oligonucleotides to the nucleic acid strands. The adaptor oligonucleotide is then removed. Nucleic acid-encoded chemical libraries, and methods of producing or screening such libraries are provided.Type: GrantFiled: December 11, 2014Date of Patent: March 26, 2019Assignee: PHILOCHEM AGInventors: Willy Decurtins, Raphael Franzini, Dario Neri, Jörg Scheuermann, Moreno Wichert
-
Patent number: 10176128Abstract: A communication system for inter-chip communication includes system processors that communicate with one another via data channels of a communication bus. A processor designated as a master processor assumes control of the transmission to the other processor designated as a slave processor. A data channel is operated in a separate physical communication bus for each data communication direction.Type: GrantFiled: September 25, 2014Date of Patent: January 8, 2019Assignee: Continental Automotive GmbHInventors: Torsten Hildebrand, Jörn Thiele, Jörg Scheuermann
-
Publication number: 20180280523Abstract: A binding moiety (B) for Carbonic Anhydrase IX (CAIX), the binding moiety comprising: The binding moiety is univalent, bivalent, or multivalent. A targeted therapeutic agent may comprise the binding moiety. The invention also includes a method for treating a disease expressing elevated levels of CAIX by administering the targeted therapeutic agent.Type: ApplicationFiled: June 11, 2018Publication date: October 4, 2018Inventors: Nikolaus Krall, Willy Decurtins, Dario Neri, Jörg Scheuermann, Moreno Wichert
-
Patent number: 10016511Abstract: A binding moiety (B) for Carbonic Anhydrase IX (CAIX), the binding moiety comprising: The binding moiety is univalent, bivalent, or multivalent. A targeted therapeutic agent may comprise the binding moiety. The invention also includes a method for treating a disease expressing elevated levels of CAIX by administering the targeted therapeutic agent.Type: GrantFiled: February 13, 2017Date of Patent: July 10, 2018Assignee: Eth ZurichInventors: Nikolaus Krall, Willy Decurtins, Dario Neri, Jörg Scheuermann, Moreno Wichert
-
Patent number: 9884122Abstract: A targeted therapeutic agent comprising a compound of formula I: B-L-D??(I), wherein: B is a low molecular weight binding moiety for Carbonic Anhydrase IX (CAIX); D is a drug moiety; and L is a linker group that undergoes cleavage in vivo for releasing said drug moiety in an active form. The drug moiety is suitably a cytotoxic agent for targeted delivery to cancer cells expressing CAIX. The binding moiety B suitably comprises a sulfonamidothiadiazole moiety. The binding moiety B may comprise one, two or more groups capable of binding to CAIX. The linker group suitably comprises a disulfide bond and/or a triazole group and/or a cleavable peptide group.Type: GrantFiled: August 2, 2016Date of Patent: February 6, 2018Assignee: Eth ZurichInventors: Nikolaus Krall, Willy Decurtins, Dario Neri, Jörg Scheuermann, Moreno Wichert
-
Publication number: 20170224831Abstract: A binding moiety (B) for Carbonic Anhydrase IX (CAIX), the binding moiety comprising: The binding moiety is univalent, bivalent, or multivalent. A targeted therapeutic agent may comprise the binding moiety. The invention also includes a method for treating a disease expressing elevated levels of CAIX by administering the targeted therapeutic agent.Type: ApplicationFiled: February 13, 2017Publication date: August 10, 2017Inventors: Nikolaus Krall, Willy Decurtins, Dario Neri, Jörg Scheuermann, Moreno Wichert
-
Publication number: 20170035892Abstract: A targeted therapeutic agent comprising a compound of formula I: B-L-D??(I), wherein: B is a low molecular weight binding moiety for Carbonic Anhydrase IX (CAIX); D is a drug moiety; and L is a linker group that undergoes cleavage in vivo for releasing said drug moiety in an active form. The drug moiety is suitably a cytotoxic agent for targeted delivery to cancer cells expressing CAIX. The binding moiety B suitably comprises a sulfonamidothiadiazole moiety. The binding moiety B may comprise one, two or more groups capable of binding to CAIX. The linker group suitably comprises a disulfide bond and/or a triazole group and/or a cleavable peptide group.Type: ApplicationFiled: August 2, 2016Publication date: February 9, 2017Inventors: Nikolaus Krall, Willy Decurtins, Dario Neri, Jörg Scheuermann, Moreno Wichert
-
Publication number: 20170009226Abstract: This invention relates to the synthesis of nucleic acid-encoded chemical libraries using common adaptor sequences. Nucleic acid strands coupled to chemical moieties may be contacted with identifier oligonucleotides comprising coding sequences encoding the chemical moieties and an adaptor oligonucleotides, such that the adaptor oligonucleotide hybridizes to both the nucleic acid strands and the identifier oligonucleotides to allow ligation of the identifier oligonucleotides to the nucleic acid strands. The adaptor oligonucleotide is then removed. Nucleic acid-encoded chemical libraries, and methods of producing or screening such libraries are provided.Type: ApplicationFiled: December 11, 2014Publication date: January 12, 2017Inventors: Willy Decurtins, Raphael Franzini, Dario Neri, Jörg Scheuermann, Moreno Wichert
-
Publication number: 20160246743Abstract: A communication system for inter-chip communication includes system processors that communicate with one another via data channels of a communication bus. A processor designated as a master processor assumes control of the transmission to the other processor designated as a slave processor.Type: ApplicationFiled: September 25, 2014Publication date: August 25, 2016Inventors: Torsten HILDEBRAND, Jörn Thiele, Jörg SCHEUERMANN